

Investigator Perspectives on Available Research Findings and Challenging Questions in Renal Cell Carcinoma

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- 1. Which of the following best describes outcomes from the Phase III TIVO-3 trial evaluating tivozanib versus sorafenib as third- or fourth-line therapy for patients with advanced renal cell carcinoma (RCC)?**
 - a. Tivozanib was better tolerated and resulted in better progression-free survival (PFS)
 - b. Tivozanib was better tolerated and resulted in inferior PFS
 - c. Tivozanib was not as well tolerated and resulted in better PFS
 - d. Tivozanib was not as well tolerated and resulted in inferior PFS
 - e. I'm not sure
- 2. Updated survival analysis from the CheckMate 9ER evaluating nivolumab combined with cabozantinib versus sunitinib in patients with previously untreated clear cell RCC demonstrated which of the following in the ITT population?**
 - a. The PFS benefit with nivolumab/cabozantinib was maintained, but the overall survival (OS) benefit was not
 - b. The PFS and OS benefits with nivolumab/cabozantinib were maintained
 - c. Neither the PFS or OS benefit with nivolumab/cabozantinib was maintained
 - d. I'm not sure
- 3. Which therapy conferred the greatest complete response rate in patients with papillary RCC in the Phase II SWOG-1500 (PAPMET) trial?**
 - a. Sunitinib
 - b. Cabozantinib
 - c. Crizotinib
 - d. Savolitinib
 - e. I'm not sure
- 4. Which of the following receptors is inhibited by zanzalintinib?**
 - a. AXL
 - b. MER
 - c. MET
 - d. VEGFR
 - e. All of the above
 - f. I'm not sure
- 5. The STELLAR-304 trial is currently evaluating zanzalintinib with nivolumab versus sunitinib in which of the following settings?**
 - a. As first-line therapy for localized clear cell RCC
 - b. After 3 or more lines of therapy for advanced clear cell RCC
 - c. As first-line therapy for advanced non clear cell RCC
 - d. After 3 or more lines of therapy for localized non-clear cell RCC
 - e. I'm not sure